216 related articles for article (PubMed ID: 27750463)
1. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
Poole A; Girard N; Clayton F; Tantravahi SK
Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463
[No Abstract] [Full Text] [Related]
2. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
3. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Ambinder AJ; Hambley B; Shanbhag S; Merrill SA
Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009
[No Abstract] [Full Text] [Related]
4. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Goldschmidt N; Rund D
Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
[No Abstract] [Full Text] [Related]
5. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Saenz-de-Viteri M; Cudrnak T
Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
[No Abstract] [Full Text] [Related]
6. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
7. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
8. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
[TBL] [Abstract][Full Text] [Related]
9. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
Sato R; Jacob J; Gaballa S
Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
[No Abstract] [Full Text] [Related]
10. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
11. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
Baron M; Zini JM; Challan Belval T; Vignon M; Denis B; Alanio A; Malphettes M
Leuk Lymphoma; 2017 Dec; 58(12):2981-2982. PubMed ID: 28554246
[No Abstract] [Full Text] [Related]
12. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
13. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
Ball S; Vutthikraivit W; Maiti A; Short NJ
Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
[No Abstract] [Full Text] [Related]
14. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
[No Abstract] [Full Text] [Related]
15. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
16. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Teh BW; Chui W; Handunnetti S; Tam C; Worth LJ; Thursky KA; Slavin MA
Leuk Lymphoma; 2019 Jun; 60(6):1572-1575. PubMed ID: 30632838
[No Abstract] [Full Text] [Related]
17. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
Wendtner CM
Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
[No Abstract] [Full Text] [Related]
18. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
Peri AM; Bisi L; Cappelletti A; Colella E; Verga L; Borella C; Foresti S; Migliorino GM; Gori A; Bandera A
Clin Microbiol Infect; 2018 Jul; 24(7):785-786. PubMed ID: 29427802
[No Abstract] [Full Text] [Related]
19. Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2014 Apr; 56(1440):29-30. PubMed ID: 24736247
[No Abstract] [Full Text] [Related]
20. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
[No Abstract] [Full Text] [Related]
[Next] [New Search]